Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.87 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.87 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.87 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249186 | 0.93 | EGFR (0.81) | EGFRERBB2ERBB4GAKHDAC3 | |
| SCHEMBL20395184 | 0.91 | EGFR (0.85) | EGFRERBB2ERBB4GAKHDAC3 | |
| SCHEMBL2525148 | 0.89 | EGFR (0.86) | EGFRERBB2ERBB4GAKHDAC2 | |
| SCHEMBL20412221 | 0.88 | EGFR (0.82) | EGFRERBB2ERBB4GAKHDAC3 | |
| SCHEMBL2248011 | 0.88 | EGFR (0.79) | EGFRERBB2ERBB4GAKHDAC3 | |
| SCHEMBL2248342 | 0.88 | EGFR (0.80) | EGFRERBB2ERBB4GAKHDAC3 | |
| SCHEMBL2253536 | 0.87 | EGFR (0.84) | EGFRERBB2ERBB4GAKHDAC3 | |
| SCHEMBL20395095 | 0.87 | EGFR (1.00) | EGFRERBB2ERBB4GAKHDAC3 | |
| SCHEMBL20395148 | 0.86 | EGFR (1.00) | EGFRERBB2ERBB4GAK | |
| SCHEMBL2509312 | 0.86 | EGFR (1.00) | EGFRERBB2ERBB4GAKHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| US-8003658-B2 | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-23 | — | — | US | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 1400/4885ERBB2 1693/4885ERBB4 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.